Reuben P Syiem¹*, Namit Ray², Krishnamoorthi R² and Rajesh Kumar²

¹Senior Resident Doctor, Department of Pharmacology, NEIGRIHMS, Shillong, India
²Post Graduate Trainee, Department of Pharmacology, NEIGRIHMS, Shillong, India

*Corresponding Author: Reuben P Syiem, Senior Resident Doctor, Department of Pharmacology, NEIGRIHMS, Shillong, India.

Received: January 15, 2025; Published: January 30, 2025

Abstract

Emerging infectious diseases (EIDs) pose significant challenges to global health, often resulting in substantial morbidity, mortal ity, and economic burden. The traditional drug development process, with its prolonged timelines and high costs, cannot adequately address the urgent need for effective therapeutics during outbreaks. Drug repurposing- leveraging approved drugs for new therapeu tic uses, has emerged as a promising strategy to combat EIDs. This review discusses the principles, methodologies, and technologies driving drug repurposing, along with its successful applications in recent pandemics, such as COVID-19 and Ebola. Regulatory and ethical challenges are analyzed, emphasizing the importance of balancing speed with safety. Finally, future perspectives, including the role of artificial intelligence and global collaboration, are explored. Drug repurposing represents a vital tool in pandemic prepared ness, offering the potential for rapid and cost-effective responses to emerging health threats

Keywords: Drug Repurposing; Emerging Infectious Diseases; Pandemic Preparedness; High-throughput Screening; COVID-19; Arti ficial Intelligence; Therapeutics

References

1. Woolhouse ME and Gowtage-Sequeria S. “Host range and emerging and reemerging pathogens”. Emergency Infectious Disease12 (2005): 1842-1847.
2. Jones KE., et al. “Global trends in emerging infectious diseases”. Nature 7181 (2008): 990-993.
3. Scannell JW., et al. “Diagnosing the decline in pharmaceutical R&D efficiency”. Nature Reviews Drug Discovery3 (2012): 191-200.
4. Paul SM., et al. “How to improve R&D productivity: the pharmaceutical industry's grand challenge”. Nature Reviews Drug Discovery3 (2012): 203-214.
5. Ashburn TT and Thor KB. “Drug repositioning: identifying and developing new uses for existing drugs”. Nature Reviews Drug Discovery8 (2004): 673-683.
6. Beigel JH., et al. “Remdesivir for the treatment of COVID-19—final report”. The New England Journal of Medicine19 (2020): 1813-1826.
7. Recovery Collaborative Group. “Dexamethasone in hospitalized patients with COVID-19”. The New England Journal of Medicine8 (2021): 693-704.
8. Nosengo N. “Can you teach old drugs new tricks?” Nature 7607 (2016): 314-316.
9. Cheng F., et al. “Network-based approach to drug repositioning”. PLOS Computational Biology 5 (2012): e1002503.
10. Subramaniam S., et al. “Mechanism-based drug repositioning for infectious diseases: approaches and challenges”. Current Opinion in Pharmacology 54 (2020): 36-43.
11. Sukhavasi S., et al. “Phenotypic screening for drug repositioning in infectious diseases”. Journal of Infectious Diseases and Therapy4 (2019): 1-9.
12. Langedijk J., et al. “Shortened development timelines for drug repurposing”. Drug Discovery Today7 (2015): 896-905.
13. Arrowsmith J. “Trial watch: Phase II failures: 2008-2010”. Nature Reviews Drug Discovery5 (2011): 328-329.
14. Xue H., et al. “Harnessing big data for drug repurposing”. Nature Reviews Drug Discovery11 (2018): 733-53.
15. Inglese J., et al. “High-throughput screening assays for drug discovery”. Nature Chemical Biology8 (2007): 466-479.
16. Chen H., et al. “Artificial intelligence in drug repurposing for infectious diseases”. Frontiers in Pharmacology 12 (2021): 661548.
17. Weston S., et al. “Harnessing omics technologies for drug repurposing in infectious diseases”. Current Opinion on Virology 41 (2020): 76-82.
18. Schneeweiss S and Avorn J. “A review of uses of health care utilization databases for epidemiologic research on therapeutics”. Journal of Clinical Epidemiology4 (2005): 323-337.
19. Wang Y., et al. “Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial”. Lancet10236 (2020): 1569-1578.
20. Kalil AC., et al. “Baricitinib plus remdesivir for hospitalized adults with COVID-19”. The New England Journal of Medicine9 (2021): 795-807.
21. Sissoko D., et al. “Experimental treatments for Ebola virus disease: the WHO MEURI framework”. Lancet 10031 (2016): 1887-1896.
22. Rocha-Pereira J., et al. “Chloroquine, a clinically approved drug, prevents Zika virus infection in human cells”. Antiviral Research 123 (2014): 17-24.
23. Chaccour C., et al. “Ivermectin to reduce malaria transmission”. Lancet Infectious Disease8 (2013): 680-681.
24. Gottlieb S. “Balancing innovation and regulation in drug repurposing”. Journal of Law Bioscience2 (2018): 307-310.
25. Ferner RE and Aronson JK. “Chloroquine and hydroxychloroquine in COVID-19”. BMJ 369 (2020): m1432.
26. Emanuel EJ., et al. “Ethical considerations for COVID-19 vaccine trials”. Science6502 (2020): 133-134.
27. Oprea TI., et al. “Drug repurposing: far beyond new targets for old drugs”. AAPS Journal 2 (2011): 236-244.
28. Collins FS and Varmus H. “A new initiative on precision medicine”. The New England Journal of Medicine9 (2015): 793-795.

Citation

Citation: Reuben P Syiem., et al. “Drug Repurposing in the Era of Emerging Infectious Diseases". Acta Scientific Pharmaceutical Sciences 9.2 (2025): 08-11.

Copyright

Copyright: © 2025 Reuben P Syiem., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.